QR kód

Development of adverse outcome pathways relevant for the identification of substances having endocrine disruption properties Uterine adenocarcinoma as adverse outcome

Abstract Development of adverse outcome pathways (AOPs) for uterine adenocarcinoma can provide a practical tool to implement the EFSA‐ECHA Guidance (2018) for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009. AOPs can give indications ab...

Celý popis

Uloženo v:
Hlavní autoři: EFSA Panel on Plant Protection Products and their Residues (PPR), Antonio F Hernandez‐Jerez, Paulien Adriaanse, Annette Aldrich, Philippe Berny, Tamara Coja, Sabine Duquesne, Andreas Focks, Maurice Millet, Olavi Pelkonen, Silvia Pieper, Aaldrik Tiktak, Christopher J Topping, Anneli Widenfalk, Martin Wilks, Gerrit Wolterink, Karine Angeli, Camilla Recordati, Majorie Van Duursen, Elisa Aiassa, Anna Lanzoni, Alfonso Lostia, Laura Martino, Irene Pilar Munoz Guajardo, Martina Panzarea, Andrea Terron, Marina Marinovich
Médium: Artigo
Jazyk:Inglês
Vydáno: Wiley 2023-02-01
Edice:EFSA Journal
Témata:
Endocrine disruption
uterine adenocarcinoma
adverse outcome pathway (AOP)
EFSA‐ECHA Guidance
On-line přístup:https://doi.org/10.2903/j.efsa.2023.7744
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky